A-Z Indication Information.

83 Indication founds starts with "F"

Follicular lymphoma	Fibromyalgia
Fat malabsortion	Fatigue
Fever	Fever & pain
Fibrocystic breast disease	Flatulance
For growing children	Functional disturbances
Fugl infec of oral cav/new bor	Fungal infections of ear
For spinl anaethe of extd durn	Filtering operatn for glaucoma
For posterior synecheia	For tired & inflammed eyes
Favus	Fissures
Fissures & infect of nipple	Flexura prurigo
Folliculitis	For rectal & vaginal lubricatn
For scalp and hairy skin inf	Freckles
Fungal & gram+ve bact infectn	Fungal infect ass dermatoses
Fungal infection of skin/nails	Fungal infections of skin
Fungal infections	Fungal infectn of mucocut junc
Fungal inflam wi infectn	Fungal infstation of extnl ear
Fungal nappy rash	Fungal/eczematised infectn
Fungl infect wi eczemt feature	Fungl/bactl mxd skin infectn
Fungl& grm +ve bac inf skn/nls	Furunculosis
Factor IX def(Christmas disea)	Filariasis
Fibrositis	Fracture/dislocation pain
Frozen shoulder	Failure of nidation
Female infertility	Frequency
Fatty infiltration of liver	Fermentative dyspepsia
Food allergies	Food poisoning
Functional G.I. disorders	Functional diarrhoea
Functional dyspepsia	Functional venous disorders
Fear	Flatulent dyspepsia
Folic acid deficiency states	Fungal infections of the eye
Free radical mediated disordr	Falciparum malaria
For palliative treatment of Hodgkins disease	For infiltration and nerve block
Facial fat loss ( lipoatrophy)	Fabry Disease
Fibrinogen Deficiency	For use in combination with Chlorambucil to treat patients with untreated lymphocytic leukemia (CLL)
For chronic weight management	For use an adjunct (add-on) treatment for seizures associated with Lennox-Gastaut syndrome in adults and children 2 years of age and older
For use in patients undergoing magnetic resonance imaging (MRI) of the central nervous system	For the Treatment of Postmenopausal Women with an Estrogen Receptor(ER)-Positive, Human Epidermal growth Factor Receptor 2 (HER2)-Negative Advanced Breast Cancer as Initial Endocrine-based Therapy for Their Metastatic Disease
For the treatment of Patients with locally Recurrent or Metastatic, Progressive, Radioactive Iodine- Refractory Differentiated Thyroid Cancer	For the treatment of Patients with Multiple Myeloma(MM), who have received at least 2 Prior Regimens,including Bortezomib and an Immunomodulatory Agent
For Complicated Urinary Tract Infections(CUTI) including Pyelonephritis and Complicated Intra-Abdominal Infections(CIAI)	For Improvement in the Appearance of Moderate to Severe Convexity or Fullness Associated with Submetal Fat in Adults
For the treatment of Moderate to Severe Plaque Psoriasis in Adult Patients who are Candidates for Systemic Therapy or Phototherapy	For the treatment of Pediatric Patients with High-Risk Neuroblastoma who Acheive at least a Partial Response to Prior First-Line Multiagent Multimodality Therapy
For the treatment of Patients with Locally Advanced Basal Cell Carcinoma(BCC) that has occurred following surgery or radiation therapy, or those who are not candidates for Surgery or Radiation Therapy	For the treatment of Patients with metastatic Non-Small Cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) substitution mutation as detected by an FDA -approved test
For use in combination with FOLFIRI for the treatment of patients with metastatic colorectal cancer (mCRC) whose disease has progressed on a first line Besvacizumab -,Oxaliplatin and Fluropyrimidine -containing regimen.	For the treatment of Philadelphia Chromosome-Negative relapsed or Refractory B-cell precusor acute Lymphpblastic Leukemia(R/R ALL)
For the treatment of patients with unresectable or metastatic melanoma and disease progression following Ipilmimab and if BRAF V600 mutation positive a BRAF Inhibitor	For the treatment of Persistent, Recurrent or Metastatic cervical cancer, in combination with Placitaxel and Cisplatin or Placitaxel and Topecan
For acute painful condition in adults